CONTENT BLOCKED PENDING BUSINESS CONFIRMATION. Neither the 2026 Professionals Catalogue nor the pricing workbook states the active composition of AminoXlean. Accurate mechanism, evidence, safety and regulatory content cannot be written without it, and publishing a metabolic product without a stated active is not defensible in any market. Note for the commercial team: the B2B pricing for AminoXlean 5 mg and 10 mg corresponds closely to the Retatrutide 5 mg and 10 mg lines in the pricing workbook, and Retatrutide is named openly in the Precision Pen range. If AminoXlean is the same active, the naming must be harmonised across vial and pen ranges and the Retatrutide monograph content applied, including its CRITICAL regulatory flag. Confirm before any content is drafted.
Active Compound: ACTIVE COMPOSITION NOT STATED IN SOURCE CATALOGUE - CONFIRMATION REQUIRED
Permitted Claim GuidelinesNone. Do not publish any content for this SKU until composition is confirmed.
Mechanism of ActionBLOCKED - Active composition required.
Evidence Grade: BLOCKED - Cannot be assessed without stated active
Clinical Evidence BaseBLOCKED - Active composition required.
Literature & ReferencesBLOCKED - Active composition required.
Safety & PrecautionsBLOCKED - Active composition required. If this product contains an incretin-class agonist, the class safety profile applies in full, including gastrointestinal effects, pancreatitis and gallbladder risk, thyroid C-cell contraindications and pregnancy contraindication.
ContraindicationsBLOCKED - Active composition required.
Storage & HandlingStore lyophilised vial at 2-8 C, protected from light.
Regulatory StatusBLOCKED. A product marketed for weight management without a disclosed active substance carries serious regulatory exposure in every target market. Do not list until composition is confirmed and reviewed.